Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475688 | 0.92 | MEN1 (0.42) | MEN1KMT2ALPAR1GAALMNA | |
| SCHEMBL8906817 | 0.90 | KMT2A (0.41) | MEN1KMT2A | |
| SCHEMBL8651345 | 0.89 | P2RX7 (0.39) | KMT2ALMNAMAPTANO1 | |
| SCHEMBL6482334 | 0.88 | GAA (0.44) | MEN1KMT2ALPAR1GAALMNA | |
| SCHEMBL6479971 | 0.87 | MEN1 (0.44) | MEN1KMT2ALPAR1GAALMNA | |
| SCHEMBL6474508 | 0.87 | MEN1 (0.40) | MEN1KMT2ALPAR1GAALMNA | |
| SCHEMBL6475241 | 0.86 | MEN1 (0.45) | MEN1KMT2ALPAR1GAALMNA | |
| SCHEMBL6483239 | 0.86 | MEN1 (0.45) | MEN1KMT2ALPAR1GAALMNA | |
| SCHEMBL6483517 | 0.86 | MEN1 (0.45) | MEN1KMT2ALPAR1GAALMNA | |
| SCHEMBL6481235 | 0.84 | MEN1 (0.42) | MEN1KMT2AGAAFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939888-B2 | 1-H-3-arylpirrolidine-2,4-dione derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-06 | — | — | US | disclosed |
| US-20040019061-A1 | 1-H-3-arylpirrolidine-2,4-dione derivatives | FISCHER REINER (DE) | 2004-01-29 | — | — | US | disclosed |
| US-6472419-B1 | 1-H-3-aryl-pyrrolidine-2, 4-dione derivatives as pest-control agents | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019061-A1 | 1-H-3-arylpirrolidine-2,4-dione derivatives | PRXL2A, DDT, CYP4B1 | MEN1 3194/4885KMT2A 2190/4885LPAR1 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.